SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Meta Says States Seek $1.4 Trillion in Penalties Over Teen Social Media Addiction Lawsuit 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
TetherMax Rebranding Highlights Official Exchange Partnerships and Transparent Operations 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
BRISBANE, Calif., May 07, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX) today announced the closing of the Company’s initial public offering of 5,000,000 shares of common stock at a public offering price of $17.00 per share, which does not include the exercise by the underwriters of their option to purchase up to an additional 750,000 shares of common stock. Aggregate gross proceeds to the Company were approximately $85.0 million, before underwriting discounts, commissions and estimated offering expenses. All of the shares in the offering were offered by UNITY. UNITY’s common stock is listed on The Nasdaq Global Select Market under the ticker symbol “UBX.”
Goldman Sachs & Co. LLC, Morgan Stanley and Citigroup acted as joint book-running managers for the offering. Mizuho Securities acted as a lead manager for the offering.
A registration statement relating to the shares sold in this offering was declared effective by the Securities and Exchange Commission on May 2, 2018. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from (1) Goldman Sachs & Co. LLC., Attention: Prospectus Department, 200 West Street, New York, NY 10282, Telephone: 1-866-471-2526; (2) Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; and (3) Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 1-800-831-9146.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About UNITY Biotechnology, Inc.
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related afflictions, such as osteoarthritis, eye diseases and pulmonary diseases. UNITY's seasoned management team has experience building companies and developing medicines.
Contact: Investors Bob Goeltz [email protected] 1-650-525-4980 Media Canale Communications Jason Spark [email protected] 1-619-849-6005
